XCancer

Exploring the Tumor Micro-Environment with 68Ga-FAPi-46 PET/CT in Breast Cancer. a Phase II Study to Evaluate the Comparison of 68Ga-FAPi-46 and 18F-FDG Uptake in Patients with Different Breast Cancer Subtypes

Description:

This study is a prospective, non-interventional, open-label study to evaluate the glucose metabolism and the expression of the imaging agent 68 Gallium-Fibroblast Activation Protein Inhibitor-46 (68Ga-FAPi-46) with PET imaging, in woman affected by Breast Cancer (BC) and referred to diagnostic imaging work-up prior to primary therapy.

Sponsor:

European Institute of Oncology

Phase:

N/A

Contacts:

Francesco Ceci

francesco.ceci@ieo.it

+390257489315

Government Study Link:

NCT06790264 - Click here to see study on

ClinicalTrials.gov

68Ga-FAPi-46

Isotope(s):
Target(s):
  • FAP